The present study aims at evaluating the anti-inflammatory effects of a novel food in older adult volunteers. Briefly, this randomized, double-blind and placebo-controlled study is performed on 91 apparently healthy older adults (age≥65 years) before and after 12 weeks' consumption of a snack enriched with camelina Sativa oil. Subjects were randomized into two groups (active group vs placebo group).
Ninety-one volunteers (26M/65F) are enrolled according to the following inclusion criteria i) free-living older adults ≥ 65 years; ii) apparently healthy subjects; iii) subjects who do not take vitamin supplements/integration and/or omega 3 polyunsaturated fatty acids; iv) subjects without food allergies. All volunteers are informed about the purpose of the study and the potential risk and provide their informed consent. Subjects are randomized into two groups: active group (13M/36F) vs placebo group (13M/29F). The main objective of this project is to test the efficacy of the 12-weeks consumption of a novel food (snack enriched with camelina Sativa oil) on the inflammatory status in older adults. The primary and secondary endpoints are: i) Investigation of changes in serum CRP levels and serum levels of pro- and anti-inflammatory cytokines, in the active group (volunteers consumed enriched snack with camelina Sativa oil) and placebo group, after 12 weeks of snacking (T1), compared to baseline (T0) (primary endpoint). ii) Evaluation of changes in serum lipid panel parameters after the consumption of the novel food in both the active and placebo groups (secondary endpoint). iii) Evaluation of changes in glucidic status after the consumption of the novel food in both the active and placebo groups (secondary endpoint). iv) Evaluation of changes in the levels of omega 3 polyunsaturated fatty acids in both the active and placebo groups (secondary endpoint). v) Evaluation of the nutritional status at T0 and at T1 in both the active and placebo groups (secondary endpoint).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Enrollment
135
Consumption of snack enriched with camelina sativa oil, twice a day for 12 weeks
Consumption of placebo snack (no enriched with camelina sativa oil), twice a day for 12 weeks
University of Pavia
Pavia, Lombardy, Italy
Inflammatory status evaluation.
Investigation of changes in serum CRP levels (pg/mL) and serum levels of pro- and anti- inflammatory cytokines (TNF-α, pg/mL; TGF-beta1, pg/mL and TGF-beta2, pg/mL; IL-18 pg/mL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Lipid panel parameters evaluation.
Evaluation of changes in serum lipid panel parameters (total cholesterol, mg/dL; triglycerides, mg/dL; HDL cholesterol, mg/dL; LDL cholesterol, mg/dL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Omega 3 polyunsaturated fatty acids evaluation.
Evaluation of changes in the levels of omega 3 polyunsaturated fatty acids.
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Glucidic profile evaluation -glucose levels
Evaluation of changes in the levels of glucose (mg/dL)
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Glucidic profile evaluation - insulin levels
Evaluation of changes in the levels of insulin (μU/mL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Glucidic profile evaluation - glycated haemoglobin levels
Evaluation of changes in the levels of glycated haemoglobin (mmol/mol).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Glucidic profile evaluation - HOMA index
Evaluation of changes in the HOMA index.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Nutritional status evaluation - hepatic function
Evaluation of nutritional status by assessing the serum levels of ALT (U/L), AST (U/L).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Nutritional status evaluation - renal function
Evaluation of nutritional status by assessing the serum levels of creatinine (mg/dL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Nutritional status evaluation.
Evaluation of nutritional status by assessing the serum levels of prealbumin (g/L).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Nutritional status evaluation - micronutrients
Evaluation of nutritional status by assessing the calcium (mg/dL), magnesium (mg/dL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Nutritional status evaluation - micronutrients
Evaluation of nutritional status by assessing the serum levels of iron (μg/dL) and zinc (μg/dL)
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Nutritional status evaluation - vitamins
Evaluation of nutritional status by assessing the serum levels of vitamin B9 (ng/mL) and vitamin D (ng/mL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Nutritional status evaluation - vitamins
Evaluation of nutritional status by assessing the serum levels of vitamin B12 (pg/mL).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Nutritional status evaluation - hyperhomocysteinemia
Evaluation of nutritional status by assessing the serum levels of Homocysteine (μM).
Time frame: Baseline (T0) and after 12 weeks of intervention (T1).
Anthropometric parameters evaluation - weight
Evaluation at baseline of weight (Kg).
Time frame: Baseline (T0).
Anthropometric parameters evaluation - height and waist circumference
Evaluation at baseline of height (cm) and waist circumference (cm).
Time frame: Baseline (T0).
Ponderal status evaluation
Evaluation at baseline of Body Mass Index (Kg/m2) to investigate the prevalence of overweight or obesity.
Time frame: Baseline (T0).
Fat distribution evaluation.
Evaluation at baseline of Waist to height ratio (WHtR) as a proxy of fat distribution and metabolic diseases risk.
Time frame: Baseline (T0).
Body composition evaluation.
Evaluation at baseline of reactance (Ohm) and resistance (Ohm) by using vectorial bioimpedance analysis.
Time frame: Baseline (T0).
Muscle strength evaluation.
Evaluation at baseline of muscle strength (Kg) by using a handgrip-dynamometer.
Time frame: Baseline (T0).